home / stock / supn / supn quote
Last: | $28.77 |
---|---|
Change Percent: | 0.58% |
Open: | $28.93 |
Close: | $28.77 |
High: | $29.37 |
Low: | $28.56 |
Volume: | 712,784 |
Last Trade Date Time: | 05/20/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$28.77 | $28.93 | $28.77 | $29.37 | $28.56 | 712,784 | 05-20-2024 |
$29.1 | $29.32 | $29.1 | $29.32 | $28.7 | 625,388 | 05-17-2024 |
$29.16 | $28.41 | $29.16 | $29.645 | $28 | 1,090,039 | 05-16-2024 |
$28.74 | $29.2 | $28.74 | $29.565 | $28.65 | 381,638 | 05-15-2024 |
$28.97 | $29.81 | $28.97 | $30.19 | $28.86 | 557,388 | 05-14-2024 |
$29.68 | $29.14 | $29.68 | $30.32 | $29.14 | 549,388 | 05-13-2024 |
$28.96 | $30.34 | $28.96 | $30.57 | $28.27 | 922,410 | 05-10-2024 |
$30 | $31.52 | $30 | $32.87 | $29.04 | 1,066,039 | 05-09-2024 |
$31.3 | $30.97 | $31.3 | $31.56 | $30.76 | 461,434 | 05-08-2024 |
$31.15 | $30.56 | $31.15 | $31.31 | $30.41 | 471,705 | 05-07-2024 |
$30.42 | $31.04 | $30.42 | $31.405 | $30.14 | 335,111 | 05-06-2024 |
$30.83 | $30.74 | $30.83 | $30.91 | $30 | 362,427 | 05-03-2024 |
$30.27 | $30.53 | $30.27 | $30.66 | $29.79 | 319,381 | 05-02-2024 |
$30.08 | $30.15 | $30.08 | $30.69 | $29.99 | 394,210 | 05-01-2024 |
$30.1 | $30.4 | $30.1 | $30.7 | $30.03 | 288,562 | 04-30-2024 |
$30.6 | $30.35 | $30.6 | $31.27 | $30.35 | 365,488 | 04-29-2024 |
$30.07 | $29.46 | $30.07 | $30.19 | $29.17 | 330,640 | 04-26-2024 |
$29.31 | $30.03 | $29.31 | $30.22 | $29.17 | 351,464 | 04-25-2024 |
$30.26 | $29.96 | $30.26 | $30.395 | $29.82 | 201,715 | 04-24-2024 |
$29.95 | $29.75 | $29.95 | $31.84 | $29.59 | 201,175 | 04-23-2024 |
News, Short Squeeze, Breakout and More Instantly...
Supernus Pharmaceuticals Inc. Company Name:
SUPN Stock Symbol:
NASDAQ Market:
Supernus Pharmaceuticals Inc. Website:
ROCKVILLE, Md., May 09, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a biopharmaceutical company focused on developing...
ROCKVILLE, Md., May 09, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company will hold a webcast and confe...
Net sales of Qelbree ® increased 75% to $45.1 million compared to first quarter 2023. Total revenues were $143.6 million. Total revenues excluding Trokendi XR ® and Oxtellar XR ® net product sales (non-GAAP) (1) increased 12% to $100.7 million compared to first ...